Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Virtus Biotech Clinical Trials ETF (NY:BBC)

39.59 -1.57 (-3.81%)
Delayed Quote Updated: 3:30 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Virtus Biotech Clinical Trials ETF

News headline image
Venture Into High-Volatility Corners of the Market With These 3 ETFs ↗
BBC, IWC and GDXJ offer diversified exposure to clinical-stage biotech, micro-cap stocks and junior gold miners, high-risk sectors that have posted strong year-to-date gains in 2026. 
Via MarketBeat
Topics ETFs
News headline image
Innovative ETF Strategies That Are Paying Off This Summer ↗
Amid record ETF inflows, niche funds like BBC, LATR, and FMED offer targeted exposure to biotech trials, buy-now-pay-later firms, and disruptive medicine, with notable recent returns. 
Via MarketBeat
Topics ETFs
News headline image
Why Did NGNE Stock Surge 25% In Pre-Market Today? ↗
The company said that the U.S. Food and Drug Administration granted a key designation for its investigational gene therapy targeting Rett syndrome. 
Via Stocktwits
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
Via Stocktwits
Topics Intellectual Property
GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount ↗
Via Stocktwits
News headline image
Why Did UPB Stock Pop 20% In Pre-Market Today? ↗
The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma. 
Via Stocktwits
News headline image
Why Did GLUE Stock Surge Over 50% In Premarket Today? ↗
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk. 
Via Stocktwits
News headline image
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation ↗
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
News headline image
ETFs Last Week: Funds Lead The Charge As Markets Stage A Return To Risk-On ↗
Investors ditched worries, boosting ETFs like VanEck SMH (+13%) on chip stock rally, Virtus BBC (+7%) on biotech hope, Simplify TESL (+31%) on Musk's focus, Invesco SPHB (+11.5%) on risk appetite,... 
Via Benzinga
Topics ETFs Economy Stocks
News headline image
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode ↗
The company reported revenue of €14.5 million for the fourth quarter, representing a decrease of €8.1 million from the corresponding period of 2023, and below an analyst estimate of €20.58, according... 
Via Stocktwits
Topics Government
News headline image
Why Is uniQure Stock Skyrocketing On Tuesday? ↗
uniQure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130. 
Via Benzinga
News headline image
Inflation Cools In June, Triggers Spike In Laggard ETFs ↗
ETFs from some beaten-down corners of the market saw smooth trading following the inflation data. 
Via Talk Markets
Topics ETFs Economy
News headline image
5 ETFs Riding High On The Biotech Comeback ↗
The high-growth biotech segment has borne the maximum brunt of the broader market sell-off. 
Via Talk Markets
News headline image
Biotech ETF Tops in June: 5 Stocks That Outperform ↗
Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%. 
Via Talk Markets
News headline image
4 Sector ETFs That Survived Market Turmoil in June ↗
Despite the broad indices’ losses, a few sector ETFs survived the turmoil. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.